Literature DB >> 24827556

Evaluation of intra- and extra-epithelial secretory IgA in chlamydial infections.

Charles W Armitage1, Connor P O'Meara, Marina C G Harvie, Peter Timms, Odilia L Wijburg, Kenneth W Beagley.   

Abstract

Immunoglobulin A is an important mucosal antibody that can neutralize mucosal pathogens by either preventing attachment to epithelia (immune exclusion) or alternatively inhibit intra-epithelial replication following transcytosis by the polymeric immunoglobulin receptor (pIgR). Chlamydia trachomatis is a major human pathogen that initially targets the endocervical or urethral epithelium in women and men, respectively. As both tissues contain abundant secretory IgA (SIgA) we assessed the protection afforded by IgA targeting different chlamydial antigens expressed during the extra- and intra-epithelial stages of infection. We developed an in vitro model using polarizing cells expressing the murine pIgR together with antigen-specific mouse IgA, and an in vivo model using pIgR(-/-) mice. Secretory IgA targeting the extra-epithelial chlamydial antigen, the major outer membrane protein, significantly reduced infection in vitro by 24% and in vivo by 44%. Conversely, pIgR-mediated delivery of IgA targeting the intra-epithelial inclusion membrane protein A bound to the inclusion but did not reduce infection in vitro or in vivo. Similarly, intra-epithelial IgA targeting the secreted protease Chlamydia protease-like activity factor also failed to reduce infection. Together, these data suggest the importance of pIgR-mediated delivery of IgA targeting extra-epithelial, but not intra-epithelial, chlamydial antigens for protection against a genital tract infection.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Chlamydia; antibodies; polymeric immunoglobulin receptor; vaccination

Mesh:

Substances:

Year:  2014        PMID: 24827556      PMCID: PMC4253500          DOI: 10.1111/imm.12317

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  Urethral cytokine and immune responses in Chlamydia trachomatis-infected males.

Authors:  M S Pate; S R Hedges; D A Sibley; M W Russell; E W Hook; J Mestecky
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  Determination of the physical environment within the Chlamydia trachomatis inclusion using ion-selective ratiometric probes.

Authors:  Scott Grieshaber; Joel A Swanson; Ted Hackstadt
Journal:  Cell Microbiol       Date:  2002-05       Impact factor: 3.715

3.  Generation of female genital tract antibody responses by local or central (common) mucosal immunization.

Authors:  H Y Wu; S Abdu; D Stinson; M W Russell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.

Authors:  Ries Langley; Bruce Wines; Natasha Willoughby; Indira Basu; Thomas Proft; John D Fraser
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

5.  The arrested immunity hypothesis and the epidemiology of chlamydia control.

Authors:  Robert C Brunham; Michael L Rekart
Journal:  Sex Transm Dis       Date:  2008-01       Impact factor: 2.830

6.  Intraepithelial cell neutralization of HIV-1 replication by IgA.

Authors:  Yung T Huang; Alison Wright; Xing Gao; Lesya Kulick; Huimin Yan; Michael E Lamm
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

7.  The Chlamydia trachomatis IncA protein is required for homotypic vesicle fusion.

Authors:  T Hackstadt; M A Scidmore-Carlson; E I Shaw; E R Fischer
Journal:  Cell Microbiol       Date:  1999-09       Impact factor: 3.715

Review 8.  Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.

Authors:  Robert C Brunham; José Rey-Ladino
Journal:  Nat Rev Immunol       Date:  2005-02       Impact factor: 53.106

9.  Reassessing the role of the secreted protease CPAF in Chlamydia trachomatis infection through genetic approaches.

Authors:  Emily A Snavely; Marcela Kokes; Joe Dan Dunn; Hector A Saka; Bidong D Nguyen; Robert J Bastidas; Dewey G McCafferty; Raphael H Valdivia
Journal:  Pathog Dis       Date:  2014-05-16       Impact factor: 3.166

10.  Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice.

Authors:  F E Johansen; M Pekna; I N Norderhaug; B Haneberg; M A Hietala; P Krajci; C Betsholtz; P Brandtzaeg
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

View more
  11 in total

Review 1.  Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles.

Authors:  Vikram Virdi; Paloma Juarez; Veronique Boudolf; Ann Depicker
Journal:  Cell Mol Life Sci       Date:  2015-10-28       Impact factor: 9.261

2.  Comparison of Murine Cervicovaginal Infection by Chlamydial Strains: Identification of Extrusions Shed In vivo.

Authors:  Jennifer H Shaw; Amanda R Behar; Timothy A Snider; Noah A Allen; Erika I Lutter
Journal:  Front Cell Infect Microbiol       Date:  2017-02-03       Impact factor: 5.293

3.  Neutrophils Are Central to Antibody-Mediated Protection against Genital Chlamydia.

Authors:  Elizabeth K Naglak; Sandra G Morrison; Richard P Morrison
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

4.  A novel whole-bacterial enzyme linked-immunosorbant assay to quantify Chlamydia trachomatis specific antibodies reveals distinct differences between systemic and genital compartments.

Authors:  Hannah L Albritton; Pamela A Kozlowski; Rebecca A Lillis; Chris L McGowin; Julia D Siren; Stephanie N Taylor; Joyce A Ibana; Lyndsey R Buckner; Li Shen; Alison J Quayle
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

5.  Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein.

Authors:  Sharon Nyari; Shahneaz Ali Khan; Galit Rawlinson; Courtney A Waugh; Andrew Potter; Volker Gerdts; Peter Timms
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

6.  Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis.

Authors:  Emma Lorenzen; Frank Follmann; Sarah Bøje; Karin Erneholm; Anja Weinreich Olsen; Jørgen Steen Agerholm; Gregers Jungersen; Peter Andersen
Journal:  Front Immunol       Date:  2015-12-16       Impact factor: 7.561

7.  Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract.

Authors:  Jeanette Erbo Wern; Maria Rathmann Sorensen; Anja Weinreich Olsen; Peter Andersen; Frank Follmann
Journal:  Front Immunol       Date:  2017-05-17       Impact factor: 7.561

8.  Immunization of a wild koala population with a recombinant Chlamydia pecorum Major Outer Membrane Protein (MOMP) or Polymorphic Membrane Protein (PMP) based vaccine: New insights into immune response, protection and clearance.

Authors:  Marion Desclozeaux; Amy Robbins; Martina Jelocnik; Shahneaz Ali Khan; Jon Hanger; Volker Gerdts; Andrew Potter; Adam Polkinghorne; Peter Timms
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

Review 9.  The Role of the Polymeric Immunoglobulin Receptor and Secretory Immunoglobulins during Mucosal Infection and Immunity.

Authors:  Holly Turula; Christiane E Wobus
Journal:  Viruses       Date:  2018-05-03       Impact factor: 5.048

10.  The Chlamydia M278 Major Outer Membrane Peptide Encapsulated in the Poly(lactic acid)-Poly(ethylene glycol) Nanoparticulate Self-Adjuvanting Delivery System Protects Mice Against a Chlamydia muridarum Genital Tract Challenge by Stimulating Robust Systemic and Local Mucosal Immune Responses.

Authors:  Richa Verma; Rajnish Sahu; Saurabh Dixit; Skyla A Duncan; Guillermo H Giambartolomei; Shree R Singh; Vida A Dennis
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.